TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms
| dc.contributor.author | Schimmer Roman R | |
| dc.contributor.author | Kovtonyuk Larisa V | |
| dc.contributor.author | Klemm Nancy | |
| dc.contributor.author | Fullin Jonas | |
| dc.contributor.author | Stolz Sebastian M | |
| dc.contributor.author | Mueller Jan | |
| dc.contributor.author | Caiado Francisco | |
| dc.contributor.author | Kurppa Kari J | |
| dc.contributor.author | Ebert Benjamin L | |
| dc.contributor.author | Manz Markus G | |
| dc.contributor.author | Boettcher Steffen | |
| dc.contributor.organization | fi=MediCity|en=MediCity| | |
| dc.contributor.organization | fi=biolääketieteen laitos|en=Institute of Biomedicine| | |
| dc.contributor.organization-code | 1.2.246.10.2458963.20.77952289591 | |
| dc.converis.publication-id | 176305725 | |
| dc.converis.url | https://research.utu.fi/converis/portal/Publication/176305725 | |
| dc.date.accessioned | 2022-10-28T13:22:13Z | |
| dc.date.available | 2022-10-28T13:22:13Z | |
| dc.format.pagerange | 3201 | |
| dc.format.pagerange | 3206 | |
| dc.identifier.eissn | 2473-9537 | |
| dc.identifier.jour-issn | 2473-9529 | |
| dc.identifier.olddbid | 181593 | |
| dc.identifier.oldhandle | 10024/164687 | |
| dc.identifier.uri | https://www.utupub.fi/handle/11111/38596 | |
| dc.identifier.url | https://doi.org/10.1182/bloodadvances.2021005859 | |
| dc.identifier.urn | URN:NBN:fi-fe2022091559191 | |
| dc.language.iso | en | |
| dc.okm.affiliatedauthor | Kurppa, Kari | |
| dc.okm.affiliatedauthor | Dataimport, MediCity | |
| dc.okm.discipline | 3111 Biomedicine | en_GB |
| dc.okm.discipline | 3111 Biolääketieteet | fi_FI |
| dc.okm.internationalcopublication | international co-publication | |
| dc.okm.internationality | International publication | |
| dc.okm.type | B1 Scientific Journal | |
| dc.publisher | Elsevier | |
| dc.publisher.country | Netherlands | en_GB |
| dc.publisher.country | Alankomaat | fi_FI |
| dc.publisher.country-code | NL | |
| dc.relation.doi | 10.1182/bloodadvances.2021005859 | |
| dc.relation.ispartofjournal | Blood Advances | |
| dc.relation.issue | 11 | |
| dc.relation.volume | 6 | |
| dc.source.identifier | https://www.utupub.fi/handle/10024/164687 | |
| dc.title | TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms | |
| dc.year.issued | 2022 |
Tiedostot
1 - 1 / 1